CVRx (NASDAQ:CVRX) Announces Quarterly Earnings Results, Misses Estimates By $0.02 EPS

CVRx (NASDAQ:CVRX) released its earnings results on Thursday. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.02), FiscalAI reports. The firm had revenue of $13.83 million for the quarter, compared to analyst estimates of $13.93 million. CVRx had a negative return on equity of 152.35% and a negative net margin of 84.93%.

Here are the key takeaways from CVRx’s conference call:

• CVRx lowered its 2026 revenue outlook to $56 million–$57 million from $58 million–$60 million, after Q3 revenue fell 6.1% year over year to $13.8 million. Q4 revenue is expected to be $11.7 million–$12.7 million.
• Reimbursement delays at UnitedHealthcare, CVRx’s largest Medicare Advantage payer, were a major drag: the 30-day approval rate for cases handled by the company fell to about 12% from a 2025 high of 83%. CVRx is appealing denials, but says the process can take months and many customer-handled denials may not be appealed.
• Physician-champion turnover and uneven sales-team experience are slowing adoption; four of nine U.S. regions are struggling to match the growth of the five more tenured regions. Management cited early improvement in team stability but said the recovery will take time.
• CVRx reported progress in coverage and clinical evidence: two written Medicare Advantage policies now cover a combined 21% of those lives, and traditional Medicare claims data showed all submitted Q1 2026 claims were paid. In the REBALANCE real-world study, the indicated-patient group had sustained functional-class improvements and improved ejection fraction through 24 months.
• CVRx ended Q3 with $58.7 million in cash and said it has at least 18 months of runway, excluding potential additional ATM proceeds. It expects 2026 operating expenses of $99 million–$101 million after cost reductions, while continuing to invest in sales and reimbursement.

CVRx Trading Down 40.9%

Shares of CVRX opened at $0.87 on Friday. CVRx has a 12-month low of $0.77 and a 12-month high of $10.28. The company has a quick ratio of 6.87, a current ratio of 8.04 and a debt-to-equity ratio of 2.94. The stock’s 50-day moving average price is $2.08 and its 200 day moving average price is $5.16. The firm has a market capitalization of $23.14 million, a price-to-earnings ratio of -0.43 and a beta of 0.81.

Trending Headlines about CVRx

Here are the key news stories impacting CVRx this week:

• Neutral Sentiment: Trading in CVRx was temporarily paused under a Limit Up-Limit Down (LULD) volatility mechanism. The halt signals unusually volatile trading but does not, by itself, explain the move. Trading halt notice
• Negative Sentiment: CVRx reported Q3 revenue of $13.83 million, below the roughly $13.93 million analyst expectation, and a loss of $0.52 per share versus estimates of about $0.50. Revenue declined year over year, and the company lowered its FY2026 outlook, raising concerns about growth and execution. CVRx reports Q3 revenue decline and lowers outlook
• Negative Sentiment: Canaccord Genuity cut its rating from Buy to Hold and reduced its price target from $5 to $2. William Blair also downgraded the stock, moving from Outperform to Market Perform. The lowered ratings and targets add pressure despite the $2 target remaining above the recent share price. William Blair downgrade

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Lake Street Capital lowered CVRx from a “buy” rating to a “hold” rating and reduced their target price for the company from $14.00 to $3.50 in a report on Friday, August 7th. Cantor Fitzgerald decreased their price target on shares of CVRx from $13.00 to $5.00 and set an “overweight” rating on the stock in a research note on Monday, August 17th. Piper Sandler lowered CVRx from an “overweight” rating to a “neutral” rating and set a $4.00 price target on the stock. in a research note on Friday, August 7th. Craig Hallum lowered shares of CVRx from a “buy” rating to a “hold” rating and set a $4.00 target price for the company. in a report on Friday, August 7th. Finally, Canaccord Genuity Group cut shares of CVRx from a “buy” rating to a “hold” rating and reduced their price target for the stock from $5.00 to $2.00 in a research report on Friday. One analyst has rated the stock with a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $3.70.

Insider Activity

In other CVRx news, COO Brent Binkowski bought 26,223 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The stock was bought at an average price of $2.91 per share, for a total transaction of $76,308.93. Following the completion of the acquisition, the chief operating officer directly owned 56,514 shares in the company, valued at $164,455.74. The trade was a 86.57% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink. Company insiders own 16.60% of the company’s stock.

About CVRx

CVRx, Inc (NASDAQ: CVRX) is a medical device company focused on developing and commercializing neuromodulation therapies for patients with cardiovascular diseases. The company’s technology is designed to activate the body’s natural nervous system pathways to help regulate cardiovascular function.

CVRx’s primary product is the Barostim system, an implantable device that delivers electrical stimulation to baroreceptors located near the carotid arteries. By influencing signals between the cardiovascular system and the brain, Barostim is intended to reduce excessive sympathetic nervous system activity and improve symptoms and function in certain patients with heart failure.